This report synthesizes the conclusions and clinical experience of three discussion groups comprised of expert neurologists, focusing on the management of key non-motor symptoms in Parkinson's disease: pain, mood, and sleep. Addressing these dimensions is a strategic pillar for transforming patients' quality of life, as they often represent a burden that is as significant as or greater than motor symptoms. The objective of this document is to delineate prevailing treatment strategies, persistent clinical challenges, and the emergent role of safinamide, predicated on the evidence discussed and the practical experience shared by the panelists. The ensuing discourse will meticulously examine each of the three symptom domains that have been deliberated by the aforementioned expert groups.